中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2014年
28期
14-15
,共2页
王水%朱海涛%朱余龙%戴晓峰
王水%硃海濤%硃餘龍%戴曉峰
왕수%주해도%주여룡%대효봉
富血小板血浆%骨折不愈合
富血小闆血漿%骨摺不愈閤
부혈소판혈장%골절불유합
Platelet rich plasma%Bone nonunion
目的:探讨骨折断端间注射富血小板血浆(PRP)治疗胫骨骨折术后骨折不愈合的临床疗效。方法将11例胫骨骨折内固定术后骨折不愈合,同意使用PRP注射的患者列为实验组;将不同意使用PRP骨折断端注射的9例患者列为对照组。每月复查X线。复查随访3~6个月。结果注射PRP组随访至6个月时X线片示骨折完全愈合4例,骨痂生长增多5例,2例患者无改变,有效率81.82%。对照组随访至6个月时X线片示骨折完全愈合1例,骨痂生长增多2例,6例患者骨折断端无改变,有效率33.33%。结论骨折断端间注射PRP能够有效促进骨折断端的修复,加快新骨形成,同时提高新生骨质量。
目的:探討骨摺斷耑間註射富血小闆血漿(PRP)治療脛骨骨摺術後骨摺不愈閤的臨床療效。方法將11例脛骨骨摺內固定術後骨摺不愈閤,同意使用PRP註射的患者列為實驗組;將不同意使用PRP骨摺斷耑註射的9例患者列為對照組。每月複查X線。複查隨訪3~6箇月。結果註射PRP組隨訪至6箇月時X線片示骨摺完全愈閤4例,骨痂生長增多5例,2例患者無改變,有效率81.82%。對照組隨訪至6箇月時X線片示骨摺完全愈閤1例,骨痂生長增多2例,6例患者骨摺斷耑無改變,有效率33.33%。結論骨摺斷耑間註射PRP能夠有效促進骨摺斷耑的脩複,加快新骨形成,同時提高新生骨質量。
목적:탐토골절단단간주사부혈소판혈장(PRP)치료경골골절술후골절불유합적림상료효。방법장11례경골골절내고정술후골절불유합,동의사용PRP주사적환자렬위실험조;장불동의사용PRP골절단단주사적9례환자렬위대조조。매월복사X선。복사수방3~6개월。결과주사PRP조수방지6개월시X선편시골절완전유합4례,골가생장증다5례,2례환자무개변,유효솔81.82%。대조조수방지6개월시X선편시골절완전유합1례,골가생장증다2례,6례환자골절단단무개변,유효솔33.33%。결론골절단단간주사PRP능구유효촉진골절단단적수복,가쾌신골형성,동시제고신생골질량。
ObjectiveTo study the clinical effection of platelet rich plasma (PRP) injection between tibial fracture end.Methods 11 cases of tibial fracture internal fixation of fracture nonunion, agreed to the use of PRP injection as experimental group, patients will not agree to use the PRP of fracture end injection of 9 patients as control group, a monthly review of X-ray review 3 to 6 months of follow-up.Results The injection of the PRP group at the time of 6 months follow-up X line piece fracture healed completely in 4 cases, callus growth markedly increased in 5 cases, 2 case of patients with no change, the effective rate was 81.82%. Control group at the time of 6 months follow-up X line piece fracture healed completely in 1 cases, callus growth markedly increased in 2 cases, 6 cases of fracture end without change, the effective rate was 33.33%.Conclusion The PRP injection between the fracture end can effectively promote the bone defect repair, accelerate the new bone formation, at the same time improve the quality of new bone.